Colourful i-Base graphic. The main text reads: GLP-1 agonists like Ozempic might help people beat drug addiction. At the top is i-Base’s website address: I hyphen base dot info. A smaller rectangle in the bottom right, reads: HIV news. 2026. There are various dotted patterns. The colours used in the image are two shades of khaki green, dark purple, light blue, blue, pink, turquoise, orange, dark green, mustard and white.

New paper in @bmj.com shows GLP-1 receptor agonists can tackle #SubstanceUseDisorder:

i-base.info/htb/53421

Could they also help to break #chemsex addiction?

#HIVsky #GUMsky #HIV #PLWH #PWH #HIVpositive #GLP1s #GLP1ReceptorAgonists #Ozempic #Wegovy #Mounjaro #semaglutide #tirzepatide #addiction

Major changes to type 2 diabetes treatment could save thousands of lives

#NICE #type2diabetes #NICEguidance #NHSsavings #dapagliflozin #NICEfinalguidance #SGLT2inhibitor #flozins #NHScostsavings #SGLT2medicines #clinicallyequivalentgenerics #GLP1receptoragonists #NICEguidelines #healthinequalities #NHSType2DiabetesPathtoRemissionProgramme
zurl.co/0vbyO

The image shows three graphs comparing the cumulative event rates of major adverse limb events, nontraumatic amputation, and lower limb revascularization between DPP4is and GLP-1 RAs over a 5-year follow-up period, with number at risk (%) values at each year.

In patients with #Diabetes and prior major adverse limb events, treatment with #GLP1ReceptorAgonists was associated with reduced risk of limb events, cardiovascular events, progression to dialysis, and all-cause mortality vs DPP-4 inhibitors.

ja.ma/3NUfSFQ

Obesity, complexity, and the lab: What 2025 taught us, and what comes next The complexity of working with the patient population in obesity continues to challenge traditional trial design. hVIVO looks to the year ahead.

#Obesity #cardiometabolicdiseases #earlyphaseresearch #clinicaltrialdesign #clinicaldevelopment #clinicaltrialsponsors #weightloss #obesitydrivencomorbidities #GLP1receptoragonists #MASLD #patientrecruitment #Personalisedtrialdesign #obesitytrials #cardiometabolicsector
zurl.co/ErmB8

16-17 GLP-1 - Weight expectations As an occupation at the very epicentre of healthcare, the nurse is a constant and iconic presence. In this edition of PharmaTimes, we demonstrate how this reassuring and essential presence within our ...

#weightlossmedications #obesity #weightmanagement #onlineprescribing #GLP1receptoragonists #GLP1RAs #Privateprescribingplatforms #GeneralPharmaceuticalCouncil #onlineprescribingplatforms #MHRA #LMCs #BMA #CQC #GLP1RAprescriptions #digitalhealthservices #nationalprescribingregistry
zurl.co/XFSNp

New NHS diabetes strategy could raise GLP-1 drug use New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments

#NHSdiabetesstrategy #GLP1 #NHS #type2diabetes #personalisedapproach #expandedaccess #GLP1agonisttherapies #NHScosts #Individualisedcare #NICEdraftguidance #NICE #SGLT2inhibitors #GLP1receptoragonists #NICEguidance #NHS10Yearplan #patientadvocacy #DiabetesUK
pharmaphorum.com/news/new-nhs...

UK probes link between GLP-1 drugs and pancreatitis The UK is studying cases of pancreatitis in people taking GLP-1 drugs for weight loss or type 2 diabetes to see if genetics may make them vulnerable.

#GLP1drugs #pancreatitis #MHRA #GLP1receptoragonists #weightloss #type2diabetes #GLP1sideeffects #MHRA #GenomicsEngland #NovoNordisk #Ozempic #Wegovy #semaglutide #EliLilly #Mounjaro #tirzepatide #chronicpancreatitis #YellowCardBiobankproject
pharmaphorum.com/news/uk-prob...

Eli Lilly and Camurus enter cardiometabolic health partnership worth up to $870m - PMLiVE The deal gives Lilly exclusive global rights to incretin products based on Camurus’ technology

#EliLilly #Camurus #cardiometabolichealth #incretinproducts #FluidCrystal #dualGIPandGLP1receptoragonists #tripleGIP #glucagonreceptoragonists #GLP1receptoragonists #amylinreceptoragonists #obesity #diabetes #RNAitherapeutics #OliXPharmaceuticals #MASH
pmlive.com/pharma_news/...

UK weight loss market: M&A opportunities Explore the latest M&A opportunities in the UK weight loss market, including market access for products like Wegovy and Mounjaro. Stay informed about key trends and opportunities in the industry.

#Obesity #GLP1receptoragonists #NovoNordisk #Wegovy #EliLilly #Mounjaro #CagriSema #Pfizer #AstraZeneca #VikingTherapeutics #VerdivaBio #Versanis #Bimagrumab #InversagoPharma #oralCB1inverseagonist #Roche #CarmotTherapeutics #NHSDigitalWeightManagementProgramme
pharmaphorum.com/market-acces...

UK regulator warns against buying weight-loss medicines without prescription - PharmaTimes MHRA urges caution over illegal medicines from beauty salons and social media

#pharmaceuticals #obesity #weightlossmedicines #MHRA #illegalmedicines
#MedicinesandHealthcareproductsRegulatoryAgency #licensedweightlossmedicines #GLP1ReceptorAgonists #YellowCardscheme #fakepharmacywebsites #onlinepharmacies #GeneralPharmaceuticalCouncil
pharmatimes.com/news/uk-regu...

Innovative Treatments for Diabetes You Need to Know About


#artificialpancreas #closedloopinsulindelivery #continuousglucosemonitoring #diabetes #genetherapy #GLP1ReceptorAgonists #innovativetreatments #isletcelltransplantation #SGLT2inhibitors #smartinsulin
thediabeticwriter.com/?p=6518